Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: May 26, 2026
Integrating single-cell biophysical and transcriptomic features to resolve functional heterogeneity in mantle cell lymphoma.
Journal: Science advances
Published: December 05, 2025
Integrating Single-Cell Biophysical and Transcriptomic Features to Resolve Functional Heterogeneity in Mantle Cell Lymphoma.
Journal: bioRxiv : the preprint server for biology
Published: June 06, 2025
A phase-2 study of pembrolizumab in patients with biologically selected subtypes of relapsed/refractory aggressive lymphomas.
Journal: Leukemia & lymphoma
Published: March 26, 2025
Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 18, 2025
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 07, 2024
Last Updated: 09/26/2026